Biology
The human body constantly regulates itself - temperature, immunity, metabolism through a delicate system called homeostasis.
Inflammation is part of this system.
It protects. It heals. But when it doesn’t stop, it harms.
Chronic inflammation sits at the core of many serious diseases.
We don’t just suppress symptoms.
We aim to restore balance at the source.
In Indian philosophy, balance sustains life.
We apply this principle to biology where disease emerges when balance is lost.
Abundance
The biological universe is vast. Millions of proteins, trillions of interactions yet only a fraction explored.
Prosperity
Our pursuit is simple: help people live healthier, longer lives.
Harmony
Every system in the body thrives on balance. When it breaks, disease emerges.
What We’re Building
We are building a new class of therapies grounded in precision immunology - targeting the exact mechanisms that drive disease.
01
Precision Immunology
Deep understanding of immune pathways driving inflammation, with a differentiated view of C3aR across key cytokine systems.
02
Precision Chemistry
Computational chemistry, physics-based AI/ML and structural biology applied to identify and design molecules for complex GPCR targets.
03
Precision Execution
Focused experiments, sharp screening and disciplined decision-making - optimised for speed and capital efficiency.
Our Edge
We focus on GPCR biology - one of the most successful classes of drug targets - with significant untapped potential.
One mechanism. Broad therapeutic potential.
Our pipeline is focused on immune-driven diseases with high unmet need, leveraging a key mechanism with broad biological reach.
Asthma
Nebuliser / Dry Powder
COPD
Nebuliser / Dry Powder
CRSwNP
Oral / Nasal Spray
Kidney
Oral
Others
Oral
Team
Our founding team brings decades of experience across discovery, development, strategy and commercialisation.
Dr Abishek Iyer
18+ years in drug discovery spanning academia and industry. Established discovery lab and led cross-functional teams at Alembic Pharma. Experience in GPCR targets including GLP-1R, PAR2, C5aR and C3aR.
Mr Jesal Shah
30+ years across pharmaceuticals and investments. Led US generic and innovation strategy for 10 years managing teams across Medical, Peptides, Discovery, IP. Identified & executed cross-border in-licensing and strategic investment transactions in innovation.
Dr MS Mohan
40+ years in R&D leadership. Founded Orbicular Pharma for developing complex generic products. Leadership roles across big pharma organisations. Developed and launched oral solids, injectables, inhalation and topical products in regulated markets.
Dr Rahul Gawande
25+ years experience across pharmaceutical manufacturing, operational scale-up and execution within regulated healthcare environments.
For decades, many therapies have relied on broadly suppressing disease pathways - often at the cost of precision, durability or tolerability.
We believe the future of medicine will come from targeting the specific biological mechanisms that drive disease at its source. As our understanding of human biology deepens, therapeutics can become more targeted, more scalable, and ultimately more effective for patients.
